Edition:
Deutschland

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,678JPY
15 Feb 2019
Change (% chg)

¥2 (+0.12%)
Prev Close
¥1,676
Open
¥1,654
Day's High
¥1,684
Day's Low
¥1,648
Volume
6,494,800
Avg. Vol
6,773,066
52-wk High
¥2,056
52-wk Low
¥1,356

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Buy/Sell

Sell Hold Buy
2.85 Mean rating from 13 analysts

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

Suspected potassium cyanide sent to Japanese newspapers, drug and food companies - media

TOKYO Envelopes containing threatening letters and a powder believed to be potassium cyanide have been sent to over a dozen Japanese companies including newspapers and drug makers over the past several days, local media reported on Tuesday.

Suspected potassium cyanide sent to Japanese newspapers, drug and food companies - media

TOKYO, Jan 29 Envelopes containing threatening letters and a powder believed to be potassium cyanide have been sent to over a dozen Japanese companies including newspapers and drug makers over the past several days, local media reported on Tuesday.

Nikkei rises on U.S.-Sino trade optimism; Nidec dives

TOKYO, Jan 18 Japan's Nikkei rose on Friday morning to its best level in a month tracking a rally on Wall Street as hopes of a resolution to the U.S.-China trade dispute boosted risk appetite, while motor maker Nidec tumbled on its dismal earnings outlook.

Nikkei rises for 3rd day on trade optimism; chip stocks underperform

* Goldman Sachs report, Samsung profit estimate drag on chip firms China's market rally supports sentiment

Nikkei rises for a 3rd day on trade optimism; chip-related shares underperform

* GS report, Samsung's weak Q4 profit estimate pulls down chip shares

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website https://bit.ly/2SjB8CL.

UPDATE 1-U.S. appeals court declines J&J bid to stop generic Zytiga sales

Nov 21 A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for a temporary restraining order blocking sales of generic versions of its blockbuster prostate cancer drug Zytiga from hitting the U.S. market.

U.S. appeals court declines J&J bid to stop generic Zytiga sales

Nov 21 A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for an temporary restraining order blocking sales of generic versions of its cancer drug Zytiga from hitting the U.S. market.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +1.02%
Rohstoffe +0.94%
Industrie +0.65%
Konjunktur abhängige Waren & Dienstleistungen +0.77%
Konjunktur unabhängige Waren & Dienstleistungen +1.46%
Finanzindustrie +1.41%
Pharma +0.40%
Technologie +1.11%
Telekommunikation +0.29%